The researchers have identified that mutations in the CREBBP gene contribute to chemotherapy resistance in B-ALL, and inhibiting this gene can alter B-cell fat metabolism.

Venetoclax works by targeting the BCL2 protein in B-cells to promote apoptosis, although its effectiveness in B-ALL has been inconsistent.

In contrast to CAR-T therapy, which permanently eliminates the body's ability to produce B-cells, this new combination therapy allows for B-cell recovery after treatment, suggesting a safer alternative.

In preclinical models, the combination of inobrodib and venetoclax has effectively killed both normal and resistant B-cells, indicating potential for future clinical applications.

Current treatment for B-ALL typically involves over two years of chemotherapy, which can lead to severe side effects, including infections and long-term organ damage.

Dr. Simon Richardson highlighted the urgent need for more effective and less toxic treatments for this aggressive form of leukemia, especially for adult patients.

The anticipated introduction of generic versions of venetoclax may further enhance the cost-effectiveness of this new treatment.

Researchers from the University of Cambridge have developed a promising new treatment for B-cell acute lymphoblastic leukemia (B-ALL), the most common childhood cancer, by combining two drugs.

This innovative research, published in Nature Communications, focuses on the drugs venetoclax and inobrodib, which target cancerous B-cells while minimizing toxicity.

B-ALL accounts for 40% of all childhood cancers in the UK, with over 500 diagnoses each year, primarily affecting children and older patients.

Plans are underway to initiate clinical trials for this drug combination in adults and teenagers with B-ALL, building on prior safety data from trials in acute myeloid leukemia (AML).